Lyell Immunopharma Inc (LYEL)
2.60
+0.06
(+2.36%)
USD |
NASDAQ |
May 15, 15:43
Lyell Immunopharma Total Assets (Quarterly): 694.22M for March 31, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 694.22M |
| December 31, 2023 | 750.03M |
| September 30, 2023 | 794.99M |
| June 30, 2023 | 835.35M |
| March 31, 2023 | 880.45M |
| December 31, 2022 | 937.56M |
| September 30, 2022 | 977.27M |
| Date | Value |
|---|---|
| June 30, 2022 | 1.022B |
| March 31, 2022 | 1.072B |
| December 31, 2021 | 1.127B |
| September 30, 2021 | 1.198B |
| June 30, 2021 | 1.230B |
| March 31, 2021 | 877.19M |
| December 31, 2020 | 908.28M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
694.22M
Minimum
Mar 2024
1.230B
Maximum
Jun 2021
950.34M
Average
922.92M
Median
Total Assets (Quarterly) Benchmarks
| GlycoMimetics Inc | 34.20M |
| Candel Therapeutics Inc | 41.20M |
| Eliem Therapeutics Inc | 110.47M |
| Entrada Therapeutics Inc | 510.84M |
| NovaBay Pharmaceuticals Inc | 5.357M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 91.06M |
| Shareholders Equity (Quarterly) | 603.16M |
| Current Ratio | 16.51 |